

Microbial genome-wide association studies: lessons from human GWAS

Robert A. Power¹, Julian Parkhill² and Tulio de Oliveira¹⁻³

Abstract | The reduced costs of sequencing have led to whole-genome sequences for a large number of microorganisms, enabling the application of microbial genome-wide association studies (GWAS). Given the successes of human GWAS in understanding disease aetiology and identifying potential drug targets, microbial GWAS are likely to further advance our understanding of infectious diseases. These advances include insights into pressing global health problems, such as antibiotic resistance and disease transmission. In this Review, we outline the methodologies of GWAS, the current state of the field of microbial GWAS, and how lessons from human GWAS can direct the future of the field.

Genome-wide association studies

(GWAS). A hypothesis-free method that tests hundreds of thousands of variants across the genome to identify alleles that are associated with a phenotype.

Single-nucleotide polymorphisms

(SNPs). A base position where two alleles exist with a frequency of > 1% in the population.

Heritability

The proportion of phenotypic variance that is due to inherited genetic variation.

¹Africa Centre for Population Health, Nelson R. Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.

²Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.

³Centre for the AIDS Programme of Research in South Africa (CAPRISA), Private Bag X7, Durban 4013, South Africa.

Correspondence to R.A.P. rpower@afriacentre.ac.za

doi:10.1038/nrg.2016.132
Published online 14 Nov 2016

Over the past decade, genome-wide association studies (GWAS) have yielded remarkable advances in the understanding of complex traits and have identified hundreds of genetic risk variants in humans (for examples, see REFS 1–3). GWAS analyse hundreds of thousands to millions of common genetic variants, usually single-nucleotide polymorphisms (SNPs), to test for an association between each variant and a phenotype of interest (see REF. 4). GWAS have confirmed the heritability of many human traits⁵, clarified their underlying genetic architecture⁶, and have identified novel biological mechanisms and drug targets⁷. Of recent interest to infectious disease researchers are microbial GWAS, which identify risk variants on the genomes of microorganisms, such as bacteria, viruses and protozoa. With increasingly cheap and high-throughput sequencing technologies, microorganism whole-genome sequences (WGS) are now being generated on an unprecedented scale that rivals human data. Microbial GWAS provide a new opportunity to develop insights into the biological mechanisms that underlie clinical outcomes, such as drug resistance and pathogenesis. As in human GWAS, insights from microbial GWAS may lead to the identification of molecular targets for drug and vaccine development. Furthermore, identifying genetic variants through microbial GWAS will enable researchers to track the evolution and spread of pathogenic strains through populations and to synthesize microorganisms *in vitro* that have the desired clinical phenotypes.

Human GWAS provide an optimistic outlook for microbial GWAS. However, there are important differences between microbial and human genomic studies that could hinder the success of microbial GWAS or require methodological adaptations. In this Review, we first outline specific features of GWAS methods and

consider their application to microorganisms. Second, we summarize the microbial GWAS that have been carried out to date, outlining their key findings, methods and challenges. Although these studies have mainly focused on pathogenic viruses, bacteria and protozoa, and thus are the dominant focus of this Review, it is important to note that the same methods can also be applied to non-pathogenic microorganisms. Finally, we discuss the lessons that have been learned from human GWAS and anticipate the future of microbial GWAS, particularly the opportunities provided by the ability to collect GWAS data from both the host and microorganisms.

Data and methodology of GWAS

GWAS grew from the common disease common variant (CDCV) hypothesis⁸, which postulates that many high-frequency but low-effect variants contribute to disease risk. This hypothesis explained how diseases can avoid selection, manifest in complex inheritance patterns, and be genetically and phenotypically heterogeneous. GWAS aim to identify the common variants that underpin the heritability observed for many phenotypes⁹ (BOX 1). These common variants are usually in the form of bi-allelic SNPs, where two nucleotides (A, C, G or T) exist at a locus with a frequency of more than 1% in the population. Each SNP is analysed, usually through linear or logistic regression, to determine whether one allele is significantly associated with the phenotype. Effects are reported as either beta for quantitative traits or odds ratio for case–control studies. Typically, only the main effects of individual SNPs are calculated, as methods for the detection of epistatic interactions between SNPs and SNP–environment interactions are challenging owing to the additional burden of multiple testing^{10,11}.

Beta

The standardized regression coefficient, derived from linear regressions in genome-wide association studies of continuous traits. It is reported as an estimate of the effect size of a single-nucleotide polymorphism (SNP), and reflects the change in phenotype expected from carrying a copy of the reference allele of the SNP.

Odds ratio

(OR). The typical means of reporting the effect size of a single-nucleotide polymorphism in a case–control (or other binary phenotype) genome-wide association study. It is derived from a logistic regression, and represents the odds of the phenotype when carrying the reference allele, compared with the odds of the phenotype in the absence of the reference allele.

Main effects

The effects of a variant on the phenotype without accounting for any possible interactions with other variants or environmental factors.

The power of the human GWAS approach came from genotyping chips that enable the rapid calling of hundreds of thousands of SNPs from across an individual's genome. Owing to the co-inheritance of segments of the genome over generations, correlations (known as linkage disequilibrium (LD)) exist between genetic variants that are in close proximity. LD allows genotyping chips to 'tag' local genetic variation by including a single proximal SNP, and to impute additional SNPs that were not directly genotyped based on known correlations¹².

There are several differences between human GWAS and microbial GWAS (TABLE 1), one of the most important of which is the source of the genomic data. Unlike human GWAS, for which the data come from SNP genotyping chips, almost all genomic data for microorganisms come from sequencing. This affects several aspects of GWAS, particularly SNP calling, as SNPs that are detected in microbial sequencing data will not only be bi-allelic, but also tri-allelic and quad-allelic. This complicates variant calling, data storage and analysis. Matching loci to a reference genome is also of increased importance in microbial GWAS, to ensure that SNPs are called at the same location for each sample and for comparison across studies. Sequencing also affects the quality control steps that must be taken to filter SNPs and individual samples. Owing to the large number of SNPs compared with the number of samples in a study, quality control is carried out to preferentially exclude low-quality SNPs. Standard quality control in human GWAS removes the SNPs with low minor allele frequency (with a typical cut-off ranging from <1% to 5%), high missingness (>1–5%), and the SNPs that are out of Hardy–Weinberg equilibrium ($P < E-5$ or -6).

Quality control on individual samples in a human study also removes samples with a high missingness (>1–5%) or that are outliers in genome-wide homozygosity. With the exception of Hardy–Weinberg equilibrium, these same quality control metrics will remain important for microbial GWAS. However, quality control thresholds need to be established for additional metrics that capture the quality of sequencing, such as sequencing depth and Phred scores.

Adapting GWAS to microbial variants

As mentioned above, human GWAS typically focus on the effects of individual SNPs. However, focusing on the effects of SNPs alone will not always be possible in microbial GWAS. For example, in bacteria, recombination can introduce novel genes. This means that the causative genetic difference may be the presence or absence of an entire gene or set of genes. Microbial GWAS need to test this variation in gene presence alongside SNPs. In this case, lessons may come from the analysis of copy number variants (CNVs) in human GWAS. CNVs are large duplications or deletions of sections of the genome. CNV analyses test for associations between a phenotype and both specific CNVs and — owing to the rarity of specific CNVs — an individual's CNV burden. An individual's CNV burden is the proportion of their entire genome, or a region of it, that is covered by CNVs¹³. Similarly, analyses of human sequence data often test for associations with the burden of rare variants¹⁴. The contribution of variants to that burden can be weighted by their predicted functional impact. Using quantitative burdens that combine the effects of multiple genetic variants into a single variable might provide statistical methods for analysing gene presence or absence and rare variants in microbial GWAS.

Another approach to handling gene presence in microbial GWAS is defining and analysing *k*-mers¹⁵. The benefit of *k*-mers is that they simultaneously capture common variation and gene presence. Analysis of *k*-mers may also be useful owing to the larger proportion of coding sequence that is found in many microorganisms compared with humans, where only a small proportion of DNA is exonic. This is because *k*-mers can capture multiple allele differences that code for different amino acids, and thus reflect changes closer to the biological mechanism that underlies the phenotype of interest.

It is worth noting that most human GWAS have focused on the additive effects of variants. This is where each additional copy of an allele carried by a diploid organism increases the likelihood of a phenotype in a linear manner. However, owing to within-host evolution and the possibility of superinfection, some microorganisms will exhibit within-host genetic diversity. Within-host diversity will lead to non-discrete SNP calling, where the frequency of an allele reflects its frequency on microbial sequences within the host, rather than the presence or absence of an allele. Although testing for a linear association between allele frequency and phenotype makes pragmatic sense, the possibility of non-linear effects also exists. Further, within-host diversity

Box 1 | Heritability

The goal of genome-wide association studies (GWAS) is to identify the variants that determine heritable phenotypes. Heritability is the proportion of variation in the phenotype that is attributable to inherited genetic similarity. Knowing the heritability of a phenotype provides practical advantages to microbial GWAS. It provides an upper limit to the extent to which the phenotype can be predicted by identified variants. For some phenotypes the heritability may be obvious, such as antibiotic resistance being the result of drug resistance mutations⁵⁹. For other phenotypes, such as HIV set point viral load, there has been debate regarding the extent to which viral genetic variants have a role⁶⁰. Microbial heritability can be established in two ways. First, by looking at the correlation in phenotype across chains of transmissions. This determines the extent to which the same microbial variants lead to the same phenotypes across individuals. Second, by estimating the extent to which phylogenetic relatedness predicts similarity in phenotype. This determines the extent to which genetically similar microorganisms are phenotypically similar.

However, heritability estimates come with several caveats. First, there is a discrepancy between what is 'genetic' and what is heritable. For example, a *de novo* genetic mutation would not be captured within heritability estimates and nor would two identical changes on an amino acid level that differed on a genetic level. Second, microbial heritability, host heritability and the environment explain the total variation in phenotype in a population. As a result, microbial heritability is relative to the amount of environmental and host variation. As the host and environment become more homogeneous the microbial heritability increases, and vice versa. This means the heritability of a phenotype can change, or remain the same, independently of whether the mean value of the phenotype changes over time. Finally, studies often estimate only additive genetic effects (known as narrow sense heritability), assuming no interaction between genes either at a single locus (dominance) or between loci (epistasis). However, uncovering epistatic interactions will be key to microbial GWAS in order to disentangle the effects of microbial variants from host background.

Table 1 | Conceptual and analytical steps of human GWAS and microbial GWAS

	Human	Microorganism
Estimation of heritability	<ul style="list-style-type: none"> • Twin studies • Adoption studies • GREML analyses 	<ul style="list-style-type: none"> • Within transmission pair correlations • Phylogenetic studies
Main source of GWAS data	SNP genotyping chips	WGS
Common study designs	<ul style="list-style-type: none"> • Case-control • Quantitative traits 	<ul style="list-style-type: none"> • Binary and quantitative traits • Longitudinal within individual sampling
Quality control steps	<ul style="list-style-type: none"> • Individual sample missingness • SNP missingness • Hardy-Weinberg equilibrium • Minor allele frequency 	<ul style="list-style-type: none"> • Sequencing depth • Poor assemblage • Minor allele frequency
Reference genomes for imputation and LD	<ul style="list-style-type: none"> • International HapMap Project • 1000 Genomes Project 	<ul style="list-style-type: none"> • RefSeq genomes • LD can be determined directly from sample
Confounding	<ul style="list-style-type: none"> • Ethnic ancestry • Population stratification • Cryptic relatedness 	<ul style="list-style-type: none"> • Subtypes or lineages • Selective sweeps • Recombination and horizontal gene transfer • Clonal expansion
Significance threshold	$P = 5E-8$	<ul style="list-style-type: none"> • Differs by species • Currently no field-wide definition
Replication	Required for publishing novel associations	<ul style="list-style-type: none"> • Not yet universally carried out • Possibility of <i>in vitro</i> validation

GWAS, genome-wide association studies; LD, linkage disequilibrium; SNP, single-nucleotide polymorphism; WGS, whole-genome sequencing.

Epistatic interactions

Interactions between variants at different locations in the genome.

Power

The probability that an analysis will reject the null hypothesis when the alternative hypothesis is true. It is influenced by numerous factors, such as the effect size and sample size.

Linkage disequilibrium (LD)

Correlations between variants due to co-inheritance. LD is usually higher between variants that are closer together, and is broken down by recombination.

Phred scores

A measure of the quality of sequencing at a given locus, specifically the confidence in the calling of alleles at that locus.

K-mers

A sequence of bases of length *k* that, in microbial genome-wide association studies, can be used as the genetic variant tested for association with the phenotype.

results in alleles from different lineages having unique LD patterns within the same host. This will be relevant to the analysis of epistatic interactions, as alleles within the same host may have different genetic backgrounds.

Finally, microbial GWAS are also likely to observe lineage effects. In this case, entire lineages, such as viral subtypes, might differ in phenotype. Thus, the lineage or subtype of the microorganism might be the genetic unit of interest, either alone or in addition to the effects of individual SNPs or *k*-mers. Disentangling the effects of a single variant from the effects that are related to lineage is potentially challenging, but has been shown to increase the power of microbial GWAS when implemented successfully¹⁶.

Confounding factors in microbial GWAS

The main challenge that is associated with GWAS is the risk of identifying seemingly causal variants that are in fact false positives¹⁷. This is due to two main causes: population structure and multiple testing (see below). The use of samples from within a genetically diverse population can lead to subtle confounding from population structure, for example, because of an excess of cases from one ethnic group. In such instances, GWAS would identify predictive SNPs that are only informative of ancestry, rather than the biology of the disease. To avoid this problem, human GWAS often restrict recruitment to ethnically homogeneous groups. Even within relatively homogeneous populations, some population structure will exist. These subtler influences of population stratification are corrected through principal

component analysis. This generates covariates that capture SNP correlations across the genome, and can be carried out using software such as EIGENSTRAT¹⁸. Principal components can capture subtle ancestry differences with high accuracy and can identify samples that represent population outliers¹⁹. Although principal components will be key to removing confounding that is due to population structure in microbial GWAS, two additional confounders exist that may require additional methods.

The first of these is homologous recombination, which occurs in bacteria and viruses through the replacement of short sequence blocks, rather than through multiple crossovers along the whole chromosome. This means that long-range LD is broken down differently in microbial genomes, leaving variants in long-range LD with each other even when short-range LD within a region is reduced²⁰. This long-range LD could make the identification of the causal variant problematic²¹. Methods that are designed for analysing historically ethnically mixed, or ‘admixed’, human populations may be helpful in this case, because they make use of recombination patterns to identify associated loci²².

The second source of confounding is that microbial population structure can represent selection on the phenotype of interest, for example, antibiotic resistance. Given the differences in frequency of recombination and selection across microorganisms, the consequent population structures are likely to range from purely clonal to nearly panmictic. In addition, the rapid spread of successful lineages may temporarily reduce their recombination with the rest of the species. In microorganisms in which there has been strong selection, it may be appropriate to use repeated samples from within a single host over time, such as comparing pretreatment and post-treatment sequences. However, this approach will not work for longitudinal phenotypes, such as the time taken to develop disease symptoms, or in microorganisms with low rates of evolution. In these studies, methods that use mixed models to account for relatedness¹⁵ or lineage effects¹⁶, or to identify signals of selection across the genome based on phylogenetic structure²³, may have more traction than typical GWAS regression methods.

Multiple testing and replication


Aside from confounding, the other major source of false positives is the multiple testing that is intrinsic to GWAS. The standard cut-off for an association to be considered statistically significant is $P = 0.05$, which represents a 5% probability of random occurrence. However, testing hundreds of thousands of SNPs leads to tens of thousands of SNPs being significant at $P < 0.05$ by chance alone. To account for the number of tests, a SNP must pass the genome-wide significance cut-off in order to be considered significant (BOX 2). This is usually $P < 5E-8$ in humans²⁴, which is approximately equal to the Bonferroni correction (a multiple testing correction) for the number of SNPs analysed in early GWAS. However, it continues to be used in more densely genotyped and imputed studies. Additional SNPs included in GWAS through deeper genotyping or imputation

Box 2 | Visualizing GWAS results

Two types of plot are used to visualize the results of genome-wide association studies (GWAS). The first is the Manhattan plot, which plots the P value of each variant against its position (see the figure). The x -axis represents the genomic location. The y -axis is the $-\log(P$ value). The logarithmic scale is used so that the most significant single-nucleotide polymorphisms (SNPs) stand out with higher values than the majority of non-significant SNPs. A reference line is used on the y -axis to reflect genome-wide significance, occasionally with a second line to represent a 'suggestive significance' threshold. Owing to the expectation of linkage disequilibrium (LD), a single highly significant SNP on its own is often interpreted as a genotyping error. Columns of significant SNPs in LD with the truly causal variant are seen in human studies, although this expectation is dependent on the LD of the organism.

The second is the quantile-quantile (QQ) plot, which compares the distribution of $-\log(P$ value)s observed in the study (y -axis) with the expected distribution under the null hypothesis (x -axis; see the figure). Departure of observed SNP P values from the $y = x$ reference line may reflect systematic inflation in the test statistics owing to population stratification. However,

departure from this line is also expected for a truly polygenic trait, as many causal SNPs may not yet have reached genome-wide significance owing to a lack of power. This will lead to an excess of low P values across all SNPs. As a result, it is the point at which the observed $-\log(P$ value)s depart the $y = x$ distribution that is important. Inflated $-\log(P$ value)s for all SNPs reflects population stratification, whereas polygenicity should lead to inflation for only those SNPs with high $-\log(P$ value)s. The QQ plot is, therefore, a qualitative judgement rather than a quantitative one. However, a calculation of the lambda value (λ ; also known as the genomic inflation factor), which is derived by dividing the median value of the observed chi-squared statistic by the median expected chi-squared statistic (for $P = 0.5$), gives a measure of the inflation in the sample. This should be 1 in the case of the null and is generally seen as inflation if above 1.05. The lambda value can be weighted by sample size to avoid polygenic inflation, as larger samples have the power to detect inflation owing to many SNPs of small effect. In this case, λ_{1000} is used to get an inflation estimate proportional to a GWAS that contained only 1,000 samples.



Superinfection

When an individual is infected with multiple strains of the same microorganism.

False positives

Variants, or any other predictors, that are identified as significantly associated with a phenotype but that are not causal. In the case of genome-wide association studies, this is usually due to confounding from population structure or insufficient quality control.

Clonal

The case in which reproduction produces genetically identical organisms, and so does not introduce novel variants or recombination.

Panmictic

A population in which clonal structure has been lost due to frequent recombination.

are in high LD with those already known, and so the correlations between SNPs reduces the number of independent tests carried out. Thus, understanding the level of LD between SNPs is important for calculating the correct threshold for genome-wide significance. Even with strict cut-offs for genome-wide significance, determining whether an association represents a false positive remains problematic.

As a result, replication in an independent cohort is the gold standard for reporting an association in GWAS²⁵. This is both to avoid false positives and to accurately estimate the effect size of the SNP. Normally, GWAS have reduced power to detect variants of small effect and there is consequently a bias towards identifying novel SNPs that have an over-estimated effect size (sometimes called the 'winner's curse')²⁶. As no bias for discovery exists during replication, the effect size in the replication cohort will more accurately reflect the true effect. Generally, replication does not require the association of a SNP to reach genome-wide significance in the replication cohort, but to pass a P value threshold based on the number of SNPs brought forward for replication. Further, meta-analysis of the P values of a SNP in both

the discovery and the replication cohorts should surpass genome-wide significance in order for a SNP to be considered a true positive.

However, microbial GWAS may be less reliant on replication than human GWAS given that suspected causal variants can be validated *in vitro*. This ability to generate carriers of identified variants and to test their effect in the laboratory reduces many of the concerns of false positives that are typically associated with human GWAS. It also provides model organisms that can be used to gain a better understanding of the function of the variant. One important area of research is the development of methods to identify and correct for epistasis. Epistasis can take the form of specific interactions between two SNPs or the effect of a SNP being conditional on a broader genetic background. Disentangling epistatic effects will be key to generating viable *in vitro* models of microbial GWAS findings and establishing causality.

Power, polygenicity and heritability

As well as providing methodological insights, the history of GWAS predicts a clear trajectory for how progress in microbial GWAS is likely to unfold. Initial human

GWAS identified only a small number of SNPs, each explaining only a tiny fraction of variation. The disparity between expected heritability from twin studies and the heritability explained by genome-wide significant associations became known as the ‘missing heritability’ (REF. 27). Missing heritability initially cast doubt on the GWAS approach. However, as the first waves of studies were pooled into meta-analyses²⁸, and the second waves of GWAS were analysed, more and more associations were reported, increasing the amount of heritability explained²⁹. It became clear that the stringent cut-off for statistical significance resulted in a need for larger sample sizes than had been expected in order to achieve sufficient power to identify SNPs. Once sufficient power was reached, the relationship between the sample size and number of SNPs identified became relatively linear. However, despite this, there was often an inverse relationship between the frequency of identified SNPs and their effect size, meaning that each SNP explained only a small fraction of variation²⁹.

The problem of missing heritability persisted, leading to a move away from single SNP analyses and towards polygenic methods³⁰ (FIG. 1). One of the first polygenic methods was the use of polygenic risk scores (PRSs)³¹. PRSs are based on the assumption that many SNPs with small effect sizes will fail the stringent cut-off that is used for genome-wide significance; however, together their cumulative effect could explain a large amount of the variance in risk. The construction of a PRS requires both a discovery and a replication cohort. In the discovery cohort, a GWAS is carried out, defining the ‘risk’ allele and effect size of each SNP regardless of whether the *P* value is significant. In the replication cohort, the number of ‘risk’ alleles that an individual sample carries is summed into a score (the PRS), with each allele weighted by its effect size. The variation in case–control status that is predicted by the PRS is then calculated. Several PRSs are often defined using different *P* value thresholds for the inclusion of SNPs from the discovery GWAS, for example, four scores using SNPs with $P < 0.001$, $P < 0.05$, $P < 0.2$ and $P < 0.5$. As more SNPs are included, there is a greater likelihood that all SNPs of true effect will be included. However, including more SNPs also increases the number of SNPs with no true effect, and thus adds noise, which causes the amount of variance that is explained to plateau. PRSs ultimately provide a more powerful predictive tool than the results of single SNPs. As such, PRSs may be key to rapidly translating the results from microbial GWAS to prediction in the clinic, even before the roles of individual risk variants are understood.

An alternative polygenic method is genomic-relatedness-matrix residual maximum likelihood analysis (GREML), which was often referred to in the early literature by the software name GCTA⁵. GREML estimates the proportion of variance that is captured by all SNPs and calculates the heritability of the phenotype. This is done by calculating how genetically similar each possible combination of two samples is (that is, their genetic relatedness). Relatedness refers to how much of the genome is shared between two samples (that is, they




Figure 1 | Phenotype prediction as GWAS sample sizes increase. Variance in a phenotype (schizophrenia³) explained in successive waves of genome-wide association studies (GWAS) by the genome-wide significant (GW-Sig) single-nucleotide polymorphisms (SNPs) and polygenic risk scores (PRSs) from all SNPs with $P < 0.05$. As can be seen, the number of SNPs identified exponentially increases with sample size, and at every stage PRSs provide substantially better prediction than the use of significant SNPs alone. However, the challenge of ‘missing heritability’ continues even within fairly large GWAS, with the variance explained still below the heritability estimates derived from GREML and twin studies. The number of cases shown reflects the discovery sample size for the PRS analysis carried out.

have the same genotypes). The heritability is then calculated as the proportion of phenotypic similarity between samples that can be explained by their relatedness. It is important to note that GREML does not estimate the true heritability of a phenotype, it estimates only the heritability that is captured by the included SNPs. Unlike PRS, GREML does not provide a means of predicting risk. However, it does act as a benchmark for the maximum amount of risk that is detectable in an infinitely powered GWAS. For example, in humans, GREML was used to estimate that common SNPs account for between one-third and one-half of the heritability estimated from twin studies³⁰ (FIG. 1). Although PRS and GREML have not been widely used in microorganisms, they will be key to understanding whether current microbial GWAS are underpowered and whether novel variants will be identified with larger sample sizes.

A crucial aspect of polygenic methods is their ability to identify what drives the heritability of a phenotype. First, polygenic methods can be used to test whether heritability is disproportionately driven by specific genomic regions, by rare or common variants, or by variants within particular biological pathways. Second, polygenic methods can measure the heritability of specific subtypes of the phenotype. Identifying phenotypic subtypes with higher

Genome-wide significance

The *P* value cut-off for declaring a variant significantly associated with a phenotype, accounting for the number of variants tested and the correlations between them.

Effect size

The proportion of variance in a phenotype predicted by a variant.

Polygenic methods

Statistical approaches that focus on the combined effects of many genetic variants rather than on the effect of any individual variant.

Table 2 | Examples of microbial GWAS

Organism	Genome size	Recombination rate	Within-host diversity	Sample size	Phenotype	Number of SNPs	Number of significant SNPs	Software	Ref.
<i>Campylobacter jejuni</i>	1.6 Mb	High	High	192	Host preference	NA	7,307 k-mers in seven genes	Bespoke	42
<i>Mycobacterium tuberculosis</i>	4 Mb	Low	Low	123	Drug resistance	24,711	50	PhyC	23
				123	Drug resistance	24,711	133	PLINK	47
				498	Drug resistance	11,704	12	PhyC	40
<i>Staphylococcus aureus</i>	2.9 Mb	Low	Low	75	Drug resistance	55,977	1	ROADTRIPS	36
				90	Virulence	3,060	121	PLINK	44
<i>Streptococcus pneumoniae</i>	2.2 Mb	High	Low	3,701	Drug resistance	392,524	301	PLINK	37
<i>Plasmodium falciparum</i>	22.9 Mb	High	Low	1,063	Drug resistance	18,322	9	FaST-LMM	41
HIV	9,000 bp	High	High	343	Drug resistance	5,100	8	PLINK	45
				1,071	Viral load	3,125	0	PLINK	43

GWAS, genome-wide association studies; NA, not applicable; SNP, single-nucleotide polymorphism.

heritability identifies individuals for whom the microbial genome is most relevant. Furthermore, polygenic methods are able to identify a genetic correlation between two phenotypes, even when data are available on only one phenotype in each sample³². Thus, they can determine whether two distinct phenotypes have overlapping aetiologies, or whether two subtypes of a phenotype are genetically distinct. Polygenic analyses have supported the generalist genes hypothesis, according to which genetic effects are highly pleiotropic³³. Overall, human GWAS predict that, for traits under moderate selection, the genetic architecture will consist of many small effect and pleiotropic variants, which are spread fairly evenly across allele frequencies and genomic regions.

Progress in microbial GWAS

Given the clear trajectory of human GWAS from underpowered studies to more advanced methods that explain a significant proportion of risk, it makes sense to ask whether microbial GWAS will advance in the same manner. Despite the complexities mentioned above, a growing number of microbial GWAS have recently been published (TABLE 2). With the exception of HIV and *Plasmodium falciparum*, these publications have generally focused on bacteria and have almost exclusively focused on pathogens within human hosts. Most genomic data have come from WGS, although genotyping chips for *P. falciparum* have existed for several years^{34,35}. Owing to the much shorter genomes of microorganisms, the number of variants analysed in microbial GWAS has been in the tens of thousands, which is orders of magnitude smaller than in human GWAS. Sample sizes have also been considerably smaller. The smallest microbial GWAS so far was a study of 75 *Staphylococcus aureus* strains³⁶ and the largest was a study of 3,701 *Streptococcus pneumoniae* isolates³⁷. The majority of studies have had sample sizes of less than 500 (TABLE 2). However, this promises to change as large multi-country consortia, such as MalariaGEN³⁸ and PANGEA_HIV³⁹, generate WGS on a much larger scale.

Despite the current small sample sizes, microbial GWAS have already been successful in identifying causal variants. This is partly due to the studies focusing on phenotypes that are under strong selection, the majority of which were studies on drug resistance. For example, microbial GWAS of *Mycobacterium tuberculosis*⁴⁰, *S. aureus*³⁶, *S. pneumoniae*³⁷, *P. falciparum*⁴¹ and HIV have all successfully identified novel drug resistance variants that often explained almost all of the phenotypic variation. Even with phenotypes under strong selection, there has been evidence of high polygenicity within microorganisms. For example, the study of drug resistance in 3,701 *S. pneumoniae* sequences identified 301 significant SNPs, with a median odds ratio of 11 (REF. 37). Given the large effect sizes, it is not surprising that many of the drug resistance variants that were identified through microbial GWAS were previously known. Although this diminishes the novelty of the findings, it also strengthens confidence in the ability of microbial GWAS to correctly identify causal variants. Another phenotype under strong selection is host specificity. Microbial GWAS of host specificity have yielded significant results for *Campylobacter jejuni*⁴² and HIV⁴³. However, within the same study of HIV host specificity, the authors found no associations between viral variants and infectiousness. The most successful study of virulence was of 90 *S. aureus* samples⁴⁴. The authors identified 121 SNPs at genome-wide significance. Functional follow-up of a subset of SNPs showed that four of 13 affected toxicity *in vivo*, suggesting that a proportion of the associations identified were truly causal.

Most microbial GWAS have so far focused on the analysis of traits that are under strong selection, but these studies have shown remarkable diversity in their analytical approaches (FIG. 2). Two analyses of HIV sequences have been carried out^{43,45}, both using the GWAS software PLINK⁴⁶. On the basis of fixed-effect models, these studies suggested that the virus shows low levels of population stratification within a single viral

Pleiotropic
Pleiotropic variants are those that have an effect on multiple distinct phenotypes.




Figure 2 | Potential models for microbial GWAS. Examples of three microbial genome-wide association study (GWAS) approaches to date^{40,41,43}. **a** | The organism analysed in each study: HIV, a retrovirus that causes AIDS; *Plasmodium falciparum*, a parasitic protozoa that is the cause of malaria; and *Mycobacterium tuberculosis*, a bacterium that causes tuberculosis. **b** | The form of geographic, population or phylogenetic confounding observed in each organism, which hinders the ability to differentiate single-nucleotide polymorphisms (SNPs) of true effect from systematic false positives. For HIV, only minimal population structure was observed, whereas for *P. falciparum* greater population differences existed. *M. tuberculosis* showed the highest level of confounding, with the different phenotypes (represented by the red and white nodes of the phylogenetic tree) mostly clustering within the same lineages. **c** | Given the different population and phylogenetic structures of the three organisms, three different approaches were used to carry out the microbial GWAS. The lack of confounding in HIV allowed for the application of typical human GWAS fixed-effect models. The more substantial population structure in *P. falciparum* was accounted for by including phylogenetic relatedness as a random effect in a mixed model. Finally, the clear phylogenetic structure of *M. tuberculosis* was used to carry out genome-wide analysis of convergent selection. **d** | How the results of each microbial GWAS were taken forwards to better understand the microorganism. For HIV, the viral genomic data were combined with human GWAS data to carry out a genome-to-genome analysis of HIV viral load. For *P. falciparum*, the information on drug resistance variants was combined with geographic data to highlight the spread of resistance variants through Southeast Asia. Finally, for *M. tuberculosis*, the identified drug resistance variant (Δald) was functionally validated by showing that carriers had improved growth comparable to other resistant strains (Bacillus Calmette–Guérin (BCG)) and sensitivity was partially restored by complementation (Δald -comp), to levels similar to those of the wild type (WT). BD, Bangladesh; MM, Myanmar; TH, Thailand; LA, Laos; VN, Vietnam. The left part of panel **d** is adapted from REF. 43. The middle part of panel **d** is from REF. 41, Nature Publishing Group. The right part of panel **d** is from REF. 40, Nature Publishing Group.

Table 3 | Features of software applications used in microbial GWAS to date

Software	Analysis	Population structure adjustment	Ref.
PLINK	Linear and logistic regression of allele count at SNPs	Ancestry informative principal components and other covariate inclusion	46
PhyC	Identifies SNPs undergoing recent convergent evolution	Based on phylogeny, so inherent	23
ROADTRIPS	Association analysis of SNP effect, allowing random variables to account for sample relatedness	Corrects for provided or derived relatedness between samples	48
FaST-LMM	Association analysis of SNP effect, allowing random variables to account for sample relatedness	Derives relatedness matrix and corrects as random effect. Principal components can be included as covariates	49
SEER	Linear and logistic regression using k-mers, simultaneously testing SNPs and gene presence or absence	Identifies relatedness from data using multidimensional scaling and generates covariates for regression	15

GWAS, genome-wide association studies; SNP, single-nucleotide polymorphism.

subtype. However, analyses of *M. tuberculosis* highlighted that although PLINK could identify many drug resistance variants, it also led to false positives owing to confounding from population structure⁴⁷. To address this limitation, the authors developed the software PhyC²³, a tool that uses phylogenetic trees to identify SNPs under recent convergent evolution. This approach identified many of the same drug resistance variants as PLINK, but reduced the level of confounding from population structure. Other studies have included phylogenetic structure as a random effect in mixed models, using software such as ROADTRIPS⁴⁸ and FaST-LMM⁴⁹. These mixed models have successfully reduced the effect of population structure in a number of microorganisms^{36,41}. One of the limitations of this software is that these programs are designed for human genomic data and cannot handle features such as within-host microbial diversity. A recent study developed a bespoke approach to microbial GWAS in the analysis of *C. jejuni*⁴². The authors generated multi-allelic k-mers, rather than SNPs, and tested these for an association with host preference. This is the only study so far to combine an analysis of SNPs with gene presence or absence, which is a key genomic feature of bacteria.

Overall, it is clear that although microbial GWAS are yielding important insights into infectious disease, the field has yet to settle on a consistent analytical approach and current methods are not yet ideally suited to microbial genomes. More refined analytical methods will become particularly important as the focus of microbial GWAS expands beyond drug resistance and towards phenotypes in which variants have subtler polygenic effects.

Remaining lessons

As microbial GWAS become more widespread, there are still several lessons that can be learned from human GWAS. Perhaps the most crucial lesson revolves around the generation of sufficient sample sizes to identify variants of small effect. This requires a collaborative approach. Samples must often be pooled from across the world in order to create well-powered discovery and replication cohorts. Of particular note is the mega-analytic

approach that pools raw genotype data from all sites into a central repository, which is used for standardized quality control and to increase power⁵⁰. There are good reasons for optimism as international microbial research consortia already exist.

One area that has not yet been explored in microbial GWAS is the trade-off between sample size and heterogeneity. As more complex phenotypes are analysed, heterogeneity will reduce power to detect the causal variants. With finite resources and time, there is a choice between focusing on collecting detailed clinical data on a smaller number of more homogeneous samples, and recruiting large numbers of samples with minimal screening. In human GWAS, both approaches have been shown to be effective. First, power can be improved by restricting to ‘super controls’ (REF. 51), for example, using controls on the opposite extreme of the phenotype of interest, or focusing on a subset of samples with a phenotype that is believed to be more homogeneous or heritable^{52,53}. Second, ‘minimal phenotyping’ can be used to maximize sample size, such as assuming all those with records of treatment are ill⁵⁴. Widely collected proxy phenotypes, such as education level as a proxy for cognitive ability, have been successfully used to maximize sample sizes for more complex traits⁵⁵. Aetiologically similar phenotypes can also be jointly analysed to maximize sample size^{2,56}. Overall, a sensible first step seems to be to increase sample sizes as much as possible. This can then be followed by secondary analyses of more homogeneous phenotypic subtypes in cases for which data are available.

Finally, many advances in human GWAS were made possible by free and open software applications (such as GCTA⁵ and PLINK⁴⁶) that could handle various data formats and could carry out multiple analyses (TABLE 3). These software applications were generally very user friendly, with detailed documentation. Microbial GWAS have so far been carried out using a range of software with different analytical approaches (TABLE 3). Although GWAS software that can handle large genomic data sets already exists, these programs are not ideally suited to the non-diploid multi-allelic nature of some microbial genomes, and cannot carry out longitudinal within-individual sequence comparisons that might be desired.

In particular, GWAS methods will need to be adapted to deal with within-host microbial diversity and recombination. Further, the successful polygenic methods for estimating the heritability and co-heritability of phenotypes from GWAS data have yet to be evaluated in microbial GWAS. As can be seen from GCTA³, a single piece of software with a topical application has driven a large number of high-profile advances in human genomics. The development of free and open software applications that can accurately and conveniently analyse a wide range of microbial WGS data to detect single SNP and polygenic effects is, therefore, a top priority of the field.

Future directions: integrating the host

Arguably, the most exciting application of microbial GWAS is to integrate it with human genomic data. Human GWAS of infectious disease have been carried out for more than 12 pathogens (reviewed in REF. 57). This Review ends by highlighting the potential for combining these findings with those of microbial GWAS. These genome-to-genome analyses can provide important insights into whether the effects of microbial variants are universal or whether they are dependent on a specific host genetic background. Such statistical host-microbial interactions would help to identify which host proteins the microorganism is interacting with on a molecular level. Further, interactions that prevent infection or disease progression would represent potential drug or vaccine targets.

The authors are aware of only one comprehensive genome-to-genome analysis at this time. The microbial GWAS of HIV set point viral load, mentioned above, generated both HIV sequences and host GWAS data⁴³. This study was able to identify many associations between viral genetic variants and those in the human genome, specifically within the major histocompatibility complex region. In a secondary analysis, the importance of

host-pathogen correlations and how they might lead to overestimates of the combined host and pathogen heritabilities were highlighted⁵⁸. In this case, although both host and viral heritability of HIV set point viral load were observed, the two were shown to substantially overlap.

With cheaper genome-sequencing methods, the ability of groups to generate both host and microbial data on the same individuals will only increase. However, just as microbial GWAS currently lack universal analytical software, so do genome-to-genome analyses. Such statistical tools will be needed in order for the field to flourish, particularly as the scale of data will make these analyses computationally intensive. A simpler method may be to condense multiple SNPs into a single variable, as seen in PRS³¹, and to test for interactions on a genome-wide level. Regardless of the method used, the availability of host and microorganism GWAS data presents an opportunity to increase power to identify causal variants. Ideally, such data will be generated within large longitudinal studies, for which genomic data can also be combined with epidemiological and clinical variables. Understanding the correlations between host demography, host heritability and microorganism heritability will provide greater insights into the extent to which microbial genomes drive clinical outcomes.

Conclusions

As this Review has discussed, there is great promise in the field of microbial GWAS. However, it is clear that a number of analytical advances will be needed to handle the unique features of microbial genomics. Perhaps the issue of greatest importance will be the development of software applications that can handle the combined analysis of host and microorganism genomic data. With these tools, we will be better able to predict individual patient outcomes, track the evolution of global epidemics, and identify new drug and vaccine targets.

- Wood, A. R. *et al.* Defining the role of common variation in the genomic and biological architecture of adult human height. *Nat. Genet.* **46**, 1173–1186 (2014).
- Jostins, L. *et al.* Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* **491**, 119–124 (2012).
- Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**, 421–427 (2014).
- Bush, W. S. & Moore, J. H. Chapter 11: genome-wide association studies. *PLoS Comput. Biol.* **8**, e1002822 (2012).
This review discusses in detail the methods, nuances and caveats of GWAS.
- Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
- Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat. Genet.* **42**, 565–569 (2010).
- Manolio, T. A. Bringing genome-wide association findings into clinical use. *Nat. Rev. Genet.* **14**, 549–558 (2013).
- Reich, D. E. & Lander, E. S. On the allelic spectrum of human disease. *Trends Genet.* **17**, 502–510 (2001).
- Hirschhorn, J. N. & Daly, M. J. Genome-wide association studies for common diseases and complex traits. *Nat. Rev. Genet.* **6**, 95–108 (2005).
- Cordell, H. J. Detecting gene-gene interactions that underlie human diseases. *Nat. Rev. Genet.* **10**, 392–404 (2009).
- Thomas, D. Gene-environment-wide association studies: emerging approaches. *Nat. Rev. Genet.* **11**, 259–272 (2010).
- Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. *Nat. Rev. Genet.* **11**, 499–511 (2010).
- Wang, K. *et al.* PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res.* **17**, 1665–1674 (2007).
- Bansal, V., Libiger, O., Torkamani, A. & Schork, N. J. Statistical analysis strategies for association studies involving rare variants. *Nat. Rev. Genet.* **11**, 773–785 (2010).
- Lees, J. A. *et al.* Sequence element enrichment analysis to determine the genetic basis of bacterial phenotypes. *Nat. Commun.* **7**, 12797 (2016).
This methods paper presents a mixed model approach to microbial GWAS, including the analysis of k-mers.
- Earle, S. G. *et al.* Identifying lineage effects when controlling for population structure improves power in bacterial association studies. *Nat. Microbiol.* **1**, 16041 (2016).
This methods paper presents an approach to disentangling the effects of single SNPs and lineage effects within microbial GWAS.
- Ioannidis, J. P., Thomas, G. & Daly, M. J. Validating, augmenting and refining genome-wide association signals. *Nat. Rev. Genet.* **10**, 318–329 (2009).
- Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat. Genet.* **38**, 904–909 (2006).
- Novembre, J. *et al.* Genes mirror geography within Europe. *Nature* **456**, 98–101 (2008).
- Didelot, X. & Maiden, M. C. Impact of recombination on bacterial evolution. *Trends Microbiol.* **18**, 315–322 (2010).
- Read, T. D. & Massey, R. C. Characterizing the genetic basis of bacterial phenotypes using genome-wide association studies: a new direction for bacteriology. *Genome Med.* **6**, 109 (2014).
The authors present an important review of the findings of bacterial GWAS.
- Rosenberg, N. A. *et al.* Genome-wide association studies in diverse populations. *Nat. Rev. Genet.* **11**, 356–366 (2010).
- Farhat, M. R. *et al.* Genomic analysis identifies targets of convergent positive selection in drug-resistant *Mycobacterium tuberculosis*. *Nat. Genet.* **45**, 1183–1189 (2013).
This microbial GWAS introduces the PhyC method, which uses phylogenetic trees to carry out a genome-wide scan of convergent evolution.
- Dudbridge, F. & Gusnanto, A. Estimation of significance thresholds for genomewide association scans. *Genet. Epidemiol.* **32**, 227–234 (2008).
- NCI-NHGRI Working Group on Replication in Association Studies *et al.* Replicating genotype-phenotype associations. *Nature* **447**, 655–660 (2007).
- Zöllner, S. & Pritchard, J. K. Overcoming the winner's curse: estimating penetrance parameters from case-control data. *Am. J. Hum. Genet.* **80**, 605–615 (2007).
- Manolio, T. A. *et al.* Finding the missing heritability of complex diseases. *Nature* **461**, 747–753 (2009).

28. Zeggini, E. & Ioannidis, J. P. Meta-analysis in genome-wide association studies. *Pharmacogenomics* **10**, 191–201 (2009).
29. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. *Am. J. Hum. Genet.* **90**, 7–24 (2012).
An important perspective on the lessons learnt from human GWAS and predictions of the future of the field.
30. Wray, N. R. *et al.* Pitfalls of predicting complex traits from SNPs. *Nat. Rev. Genet.* **14**, 507–515 (2013).
A useful review of a range of polygenic methods and their applications.
31. Purcell, S. M. *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748–752 (2009).
32. Lee, S. H., Yang, J., Goddard, M. E., Visscher, P. M. & Wray, N. R. Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. *Bioinformatics* **28**, 2540–2542 (2012).
33. Visscher, P. M. & Yang, J. A plethora of pleiotropy across complex traits. *Nat. Genet.* **48**, 707–708 (2016).
34. Tan, J. C. *et al.* An optimized microarray platform for assaying genomic variation in *Plasmodium falciparum* field populations. *Genome Biol.* **12**, R35 (2011).
35. Cheeseman, I. H. *et al.* A major genome region underlying artemisinin resistance in malaria. *Science* **336**, 79–82 (2012).
36. Alam, M. T. *et al.* Dissecting vancomycin-intermediate resistance in *Staphylococcus aureus* using genome-wide association. *Genome Biol. Evol.* **6**, 1174–1185 (2014).
37. Chewapreecha, C. *et al.* Comprehensive identification of single nucleotide polymorphisms associated with β -lactam resistance within pneumococcal mosaic genes. *PLoS Genet.* **10**, e1004547 (2014).
38. Malaria Genomic Epidemiology Network. A global network for investigating the genomic epidemiology of malaria. *Nature* **456**, 732–737 (2008).
39. Pillay, D. *et al.* PANGEA-HIV: phylogenetics for generalised epidemics in Africa. *Lancet Infect. Dis.* **15**, 259–261 (2015).
40. Desjardins, C. A. *et al.* Genomic and functional analyses of *Mycobacterium tuberculosis* strains implicate *ald* in D-cycloserine resistance. *Nat. Genet.* **48**, 544–551 (2016).
41. Miotto, O. *et al.* Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat. Genet.* **47**, 226–234 (2015).
42. Sheppard, S. K. *et al.* Genome-wide association study identifies vitamin B₅ biosynthesis as a host specificity factor in *Campylobacter*. *Proc. Natl Acad. Sci. USA* **110**, 11923–11927 (2013).
43. Bartha, I. *et al.* A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. *eLife* **2**, e011123 (2013).
An example of a genome-to-genome analysis with both host and microbial GWAS data.
44. Laabei, M. *et al.* Predicting the virulence of MRSA from its genome sequence. *Genome Res.* **24**, 839–849 (2014).
45. Power, R. A. *et al.* Genome-wide association study of HIV whole genome sequences validated using drug resistance. *PLoS ONE* **11**, e0163476 (2016).
46. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
47. Chen, P. E. & Shapiro, B. J. The advent of genome-wide association studies for bacteria. *Curr. Opin. Microbiol.* **25**, 17–24 (2015).
48. Thornton, T. & McPeck, M. S. ROADTRIPS: case-control association testing with partially or completely unknown population and pedigree structure. *Am. J. Hum. Genet.* **86**, 172–184 (2010).
49. Lippert, C. *et al.* FaST linear mixed models for genome-wide association studies. *Nat. Methods* **8**, 833–837 (2011).
50. Evangelou, E. & Ioannidis, J. P. Meta-analysis methods for genome-wide association studies and beyond. *Nat. Rev. Genet.* **14**, 379–389 (2013).
51. McCarthy, M. I. *et al.* Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat. Rev. Genet.* **9**, 356–369 (2008).
52. Traylor, M. *et al.* Using phenotypic heterogeneity to increase the power of genome-wide association studies: application to age at onset of ischaemic stroke subphenotypes. *Genet. Epidemiol.* **37**, 495–503 (2013).
53. Power, R. A. *et al.* Genome-wide association for major depression through age at onset stratification: major depressive disorder working group of the Psychiatric Genomics Consortium. *Biol. Psychiatry* <http://dx.doi.org/10.1016/j.biopsych.2016.05.010> (2016).
54. Hamshere, M. L. *et al.* Genome-wide significant associations in schizophrenia from *ITIH3/4*, *CACNA1C* and *SDCCAG8*, and extensive replication of associations reported by the Schizophrenia PGC. *Mol. Psychiatry* **18**, 708–712 (2013).
55. Rietveld, C. A. *et al.* GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. *Science* **340**, 1467–1471 (2013).
56. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* **381**, 1371–1379 (2013).
57. Chapman, S. J. & Hill, A. V. Human genetic susceptibility to infectious disease. *Nat. Rev. Genet.* **13**, 175–188 (2012).
58. Bartha, I. *et al.* Estimating the respective contributions of human and viral genetic variation to HIV control. Preprint at *bioRxiv* <http://dx.doi.org/10.1101/029017> (2015).
59. Walker, T. M. *et al.* Whole-genome sequencing for prediction of *Mycobacterium tuberculosis* drug susceptibility and resistance: a retrospective cohort study. *Lancet Infect. Dis.* **15**, 1193–1202 (2015).
60. Fraser, C. *et al.* Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. *Science* **343**, 1243727 (2014).

Acknowledgements

Research supported by a South African MRC Flagship grant (MRC-RFA-UFSP-01-2013/UKZN HIVEPI), Wellcome Trust grants (098051 and 201355/Z/16/Z) and a Royal Society Newton Advanced Fellowship.

Competing interests statement

The authors declare no competing interests.